Published in Obesity and Diabetes Week, February 13th, 2006
According to recent research published in the journal Hormone and Metabolic Research, "Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting time-action profile, has been developed to fulfill the mealtime (bolus) insulin requirement in patients with diabetes."
M. Dreyer and colleagues at Bethanien-Krankenhaus GmbH explained, "The aim of this multinational, multicenter, controlled, open-label, randomized, parallel-group study was to compare the efficacy and safety of insulin glulisine (glulisine) to that of insulin lispro (lispro) in adults diagnosed with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.